Aardvark Therapeutics has halted enrollment and dosing in its Phase 3 HERO trial and its open-label extension after reversible cardiac findings emerged at supra-therapeutic doses of ARD-101 in a healthy volunteer study. The pause pushes the company off its prior guidance for a Q3 2026 topline readout, with next steps and revised timelines slated for an update in the second quarter.
The HERO study is a randomized, double-blind, placebo-controlled Phase 3 evaluating ARD-101 for hyperphagia in Prader-Willi syndrome. In parallel, Aardvark has been advancing ARD-101 as a gut-restricted pan–TAS2R agonist intended to stimulate enteroendocrine signaling and satiety pathways, including GLP-1 and CCK. The company characterized the cardiac observations as reversible and detected at exposures above the intended therapeutic range, but nonetheless moved to pause dosing while it completes a data review and re-examines dose selection and monitoring.
Operationally, this is a defensive reset aimed at protecting the program’s regulatory credibility in a pediatric rare disease where even peripheral cardiac signals can quickly shape labeling and postmarketing commitments. Running a healthy volunteer study during Phase 3 to refine exposure margins and labeling is standard, but a safety signal at high doses tightens the program’s therapeutic index and forces a reconsideration of how much headroom is truly available above the target dose. For a mechanism positioned as gut-restricted with limited systemic exposure, any cardiology read-through—whether electrophysiologic, rate-related, or biomarker-based—will prompt questions about off-target effects, neurohumoral pathways, or interaction risk when combined with GLP-1–based regimens.
The immediate impact lands on sites and CRO partners managing PWS families already randomized or preparing for dosing. Sites will need clear instructions on washout, follow-up assessments, and whether blinded participants require additional ECGs or cardiac labs during the pause. Budget revisions, re-consenting, and recruitment pipelines will all be stressed, with retention risk rising as caregivers reassess participation without certainty on timelines. For the open-label extension population, continuity of care and patient experience will hinge on how quickly Aardvark can define a revised dose or resume under enhanced monitoring.
For regulators, the pause signals alignment with current FDA expectations around pediatric and adolescent safety, particularly in neuroendocrine and metabolic programs where heart rate and electrophysiology effects are scrutinized. The path forward likely involves a tighter exposure-response package, potential thorough QT or equivalent cardiac characterization, and protocol amendments to narrow dosing bands and embed cardiology oversight. If ARD-101 ultimately proceeds at a lower ceiling dose with added monitoring, the overall development plan remains salvageable, though statistical power and event capture may need recalibration if efficacy at reduced exposure proves attenuated.
Strategically, the ripple effects extend to Aardvark’s broader platform, including ARD-201, the fixed-dose combination with a DPP-4 inhibitor. Any finding that compresses ARD-101’s safety margin could constrain combination strategies designed to amplify incretin signaling, with implications for Phase 2 designs, dose titration, and cardiovascular monitoring requirements.
What to watch next is whether the company can quantify a clean safety window supported by PK/PD data and translate that into an FDA-endorsed protocol amendment without restarting key timelines. Clarity on the nature of the cardiac observations, revised dose justification, and added monitoring plans will dictate how quickly HERO can restart and how much of the current dataset remains usable. If Aardvark can lock in a lower, well-characterized dose with preserved efficacy and a credible cardiac package, the program can re-emerge with manageable delay. If not, expect a longer reset that tests site engagement, caregiver confidence, and the company’s ability to finance a protracted pathway in a field where late-stage competitors and adjunctive GLP-1 strategies are moving ahead.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
